Mo, 2.11.2026 | Original article from: LabRulezLCMS Webinars
13 webinars: ADCs, bioconjugates, biopharma QC, CDMS, Empower, LC-MS, lipidomics, MassHunter, method transfer, oligonucleotides, Orbitrap, SEC-MALS, viral vectors.Webinars LabRulezLCMS Week 45/2026
LabRulez / AI: Webinars LabRulezLCMS Week 45/2026
In the week of November 2, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.
👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION
👉 Search and filter in the largest global database with over 6 000 GC, LC, MS and spectroscopy webinars.
1. Waters Corporation: Bioconjugate Analysis Without the Complexity: What the USP and Waters' Newest Capabilities Bring to the Bench
- Tu, 3.11.2026 17:00 CET
Join the USP and Waters webinar on antibody-drug conjugate (ADC) analysis. Discover reference standards and inline mass deconvolution in Empower CDS.
2. Technology Networks: When Good Analytical Methods Become a Problem
- Tu, 3.11.2026 18:00 CET
Join our webinar on analytical method lifecycle management in biopharmaceuticals. Learn when and why to reassess established methods for QC and transfer.
3. Thermo Fisher Scientific: Overcome separation and MS challenges in complex biotherapeutic analyses: Practical approaches to impurity characterization, adsorption, adducts, and PTMs
- We, 4.11.2026 11:00 CET
Join the Thermo Fisher Scientific webinar on ADC and oligonucleotide bioanalysis. Discover bioinert LC and Orbitrap MS for PTM profiling and DAR assays.
4. Technology Networks: Increase Purification Throughput With Automated Sample Loading
- We, 4.11.2026 17:00 CET
Increase purification throughput with automated sample loading. Discover how the ALIAS autosampler works with ÄKTA systems across a range of chromatography applications.
5. Waters Corporation: Walk-Up Mass Confirmation for Synthetic Oligonucleotides
- We, 4.11.2026 17:00 CET
Learn how BioAccord and ReadyAccess simplify LC-MS analysis of synthetic oligonucleotides. Speed up your analysis with automatic data deconvolution in Empower.
6. Metrohm: Bring Your Work to Kids: Test, Don't Guess
- Th, 5.11.2026 10:00 CET
Join Metrohm and RI Analytical for a fun 30-minute science experience where kids become science detectives and discover how analytical testing helps keep water, toys, and everyday products safe.
7. Agilent Technologies: Beyond Conventional SEC: Deeper Molecular Insights for Biotherapeutics with SEC-MALS
- Th, 5.11.2026 11:30 CET
Join the Agilent webinar on biotherapeutic SEC-MALS. Discover calibration-independent determination of absolute molecular weight and aggregation.
8. SCIEX: SCIEX OS 5.0 software demo day
- Th, 5.11.2026 12:00 CET
Join the SCIEX OS 5.0 demo day webinar. Discover how Report Studio and the AI assistant streamline LC-MS data analysis workflows.
9. Agilent Technologies: MassHunter BioConfirm Workflows for Biomolecule Characterization
- Th, 5.11.2026 14:00 CET
Discover how MassHunter BioConfirm supports biomolecule characterization workflows.
10. Waters Corporation: LC Coffee Breaks: Why my Method Doesn't Transfer Smoothly?
- Th, 5.11.2026 14:00 CET
Discover why LC methods may fail during transfer between systems. Learn the root causes of inconsistent results and best practices for reliable, reproducible method transfer.
11. Agilent Technologies: Let's Talk - from Dissolution Sample Preparation to LC Finish
- Th, 5.11.2026 15:30 CET
Learn how to optimize dissolution testing from sample preparation through to the final LC analysis.
12. Waters Corporation: CDMS in Action: Driving Better AAV Processes and Deeper Viral Vector Insights
- Th, 5.11.2026 16:00 CET
Join the Waters and Lexeo Therapeutics webinar on CDMS. Discover how to characterize AAVs, lentiviruses, and VLPs for gene therapy applications.
13. Thermo Fisher Scientific: Multi-LC-MS Platform Plasma Steroidomic and Lipidomic Profile Analyses in BRCA1/2 Mutation Carriers and Breast Cancer Risk: A Retrospective Komen Tissue Bank Study
- Th, 5.11.2026 17:30 CET
Explore how plasma lipidomics and steroidomics may reveal metabolic changes associated with BRCA1/2 status and breast cancer risk years before diagnosis.
